Boston Scientific Corporation (BSX) Next Earnings Date & Expected ±6.2% Move

Per the Roarable RQD rating, BSX scores 62 out of 100, graded C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

• Fundamental Cash Engine: 15 / 20. Per the RQD rating, this pillar reflects ROIC of 9.2% and an FCF yield of 5.91%. For a prospective investor, this indicates moderate cash generation relative to the capital employed, with a valuation tradeoff: the FCF yield provides some support for the price but does not signal an exceptionally cheap entry.
• Whale / 13F Flow: 7 / 20. Per the RQD rating, this is the weakest pillar, covering institutional accumulation and options positioning. The source data does not include 13F holder detail, so the low score signals limited institutional conviction as measured by this model, which is a caution for a prospective investor.
• Insider Conviction: 15 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. Insider and congressional activity is moderate in the model's assessment; the underlying trade detail is not in the source data.
• Macro Regime Fit: 11 / 20. Per the RQD rating, beta is 0.99, meaning the model views BSX as roughly market-correlated in volatility, with sector sensitivity weighing on the score. An investor should expect the stock to track broad market moves rather than diverge meaningfully.
• Forensic Balance Sheet: 14 / 20. Per the RQD rating, Altman Z is 2.77, Piotroski F is 8/9, and Debt/Equity is 0.36. These metrics point to a relatively sound balance sheet, a meaningful upside driver for a prospective investor focused on financial resilience.

Overall, the composite of 62 reflects a mix of solid balance-sheet strength and cash generation offset by weak institutional flow and market-sensitivity considerations. Upside drivers include the forensic and cash pillars; the principal valuation tradeoff is that P/E (TTM) of 22 sits above forward P/E of 18.5, implying expected earnings improvement that the source data does not independently confirm.

Revenue grew from $14240.0M (FY 2023) to $20074.0M (FY 2025) per the SEC financials, and operating income rose over the same span. Reported net income is $0.0M in each period and EPS is N/A, so profitability conclusions rely on the market-data margins rather than the filed net income line. Per the Roarable RQD rating, ROIC is 9.2%, the Altman Z-Score is 2.77, the Piotroski F-Score is 8/9, and Debt/Equity is 0.36, indicating a balance sheet the model rates as sound. Reported debt rose from $7962.4M to $10219.5M while cash moved from N/A to $1965.0M.

• What specific operational, product, or regulatory events drove the 52-week decline from $105.65 to $39.57, and which of them are resolved?
• What is the source of the gap between reported net income of $0.0M and the 14% net margin cited in market data?
• What is the institutional and insider holder composition behind the 7/20 whale-flow pillar score?
• Do the Stryker comparison and "turnaround" framing reflect company-specific guidance that the source data does not capture?
• What drove the rise in debt from $7962.4M (FY 2023) to $10219.5M (FY 2025), and how is it being serviced against the $1965.0M cash position?